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Exenatide infusion decreases atrial 
natriuretic peptide levels by reducing cardiac 
filling pressures in type 2 diabetes patients 
with decompensated congestive heart failure
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Abstract 
Background: The vascular effects exerted by GLP-1 are mediated by several synergistic mechanisms such as involve-
ment of nitric oxide and natriuresis. Recently, it was demonstrated that atrial natriuretic peptide (ANP) is essential for 
the glucagon-like peptide-1 (GLP-1)-stimulated vascular smooth muscle relaxation that mediates anti-hypertensive 
action in rodents. Therefore a GLP-1–ANP axis has been suggested. The aim of this study was to investigate whether 
this effect can be demonstrated in patients with type 2 diabetes and congestive heart failure.
Methods: The study was a post hoc analysis of a randomized double-blinded, placebo-controlled trial. Twenty male 
patients with type 2 diabetes and congestive heart failure were randomized to receive a 6-h infusion of exenatide or 
placebo. Cardiac filling pressures were measured by right heart catheterization, and plasma levels of ANP, N-terminal 
pro-brain natriuretic peptide, and exenatide were measured at baseline and at the end of the exenatide infusion.
Results: Exenatide infusion resulted in a significant decrease of circulating ANP levels compared with placebo, 
concomitant with a decrease in pulmonary capillary wedge pressure (PCWP), pulmonary artery pressure (PAP) and 
right arterial pressure (RAP), and increased cardiac output. There was no correlation between plasma ANP levels and 
exenatide levels. A negative correlation between ANP levels and PCWP, PAP, and RAP, which remained significant after 
adjustment for plasma exenatide levels, was demonstrated during exenatide infusion.
Conclusions: Exenatide infusion decreases cardiac filling pressure and ANP levels. The reduction of ANP levels was 
primarily because of the reduction in cardiac filling pressure, independent of exenatide levels. It seems unlikely that 
this was mediated via ANP.
Trial registration: http://www.isrctn.org/ISRCTN47533126
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Background
Glucagon-like peptide-1 (GLP-1) is a gut-derived hor-
mone released after meal ingestion [1]. Beyond its well-
known anti-hyperglycemic actions, studies have also 
shown beneficial effects on the vasculature [2, 3] and 
heart function [4–6]. Lowering of blood pressure has 
been observed in subjects with type 2 diabetes receiving 
long-term treatment with GLP-1 receptor (GLP-1R) ago-
nists, although the mechanisms underlying this are not 
fully understood [7].
The vascular effects exerted by GLP-1 are mediated by 
several synergistic mechanisms as earlier studies have 
linked GLP-1 to both nitric oxide (NO)-dependent, and 
NO-independent vasorelaxation [3, 8, 9]. Additionally, 
antihypertensive effects of GLP-1 also might occur due 
to stimulation of natriuresis [10, 11]. Interestingly, it was 
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peptide (ANP) might be essential for GLP-1-stimulated 
vascular smooth muscle relaxation, mediating anti-
hypertensive actions. After activation of GLP-1R in car-
diomyocytes with the GLP-1 agonists liraglutide and 
exenatide, an increase in cyclic adenosine monophos-
phate promoted membrane protein translocation, result-
ing in ANP release. This in turn induced cyclic guanosine 
monophosphate-mediated smooth muscle relaxation and 
natriuresis, and consequently blood-pressure reduction 
[12]. These findings prompted the investigators to define 
a novel GLP-1R–ANP axis, shedding light on under-
standing of the mechanisms of GLP-1-induced cardio-
vascular actions [13].
ANP is synthesized and stored in secretory granules 
of atrial myocytes [14, 15]. In patients with congestive 
heart failure (CHF), circulating ANP is associated with 
functional impairment assessed by the New York Heart 
Association (NYHA) classification, as well as elevated 
atrial pressure and other parameters of CHF [16–18]. A 
recent study has shown significant correlations between 
increases in plasma natriuretic peptides and GLP-1R-ag-
onist-induced body composition changes [19]. Despite 
this, there is today no robust evidence for a GLP-1R–
ANP axis in humans [10, 20, 21]. To the best of our 
knowledge, there are no studies investigating the associa-
tion between GLP-1R and natriuretic peptides in patients 
with type 2 diabetes and CHF.
The current study is a post hoc analysis of a recently 
randomized controlled clinical trial, where the aim was 
to determine whether exenatide improves hemodynamic 
function in patients with type 2 diabetes and CHF [22]. 
Since a GLP-1R–ANP axis has been suggested in rodents 
[12], we aimed to investigate whether such an associa-
tion between GLP-1R mediated hemodynamic effects 
and plasma ANP changes in patients with decompen-
sated congestive heart failure, may take part. Therefore 
in the present study we retrospectively analyzed plasma 
levels for ANP and N-terminal pro-brain natriuretic pep-
tide (NT-proBNP) on the one hand, and hemodynamic 
parameters, i.e. cardiac index (CI), pulmonary capil-
lary wedge pressure (PCWP), pulmonary artery pres-
sure (PAP), right arterial pressure (RAP), and peripheral 




The study population comprised 20 participants with 
type 2 diabetes hospitalized for CHF. Inclusion and 
exclusion criteria have been described elsewhere [22]. 
Briefly, patients were recruited from the Stockholm 
South Hospital, Sweden. Inclusion criteria were: male 
and female sex, age 18–80 years, known type 2 diabetes, 
hospitalization for CHF according to NYHA III-IV cri-
teria, left ventricular (LV) systolic dysfunction with a 
documented LV ejection fraction of ≤35  % (assessed 
by echocardiography), and clinically stable period of 
24  h using established therapy [diuretics, angiotensin-
converting enzyme (ACE) or angiotensin-II inhibitors 
(A-II) inhibitors, and β-blockers]. Exclusion criteria 
were: type 1 diabetes, ongoing treatment with inotropic 
agents, acute coronary syndrome or documented acute 
myocardial infarction within the previous 8  weeks, 
active myocarditis, significant aortic stenosis or mitral/
tricuspidal regurgitation, symptomatic primary pul-
monary disease, ventricular arrhythmias, second-, or 
third-degree atrioventricular block, implanted cardio-
verter defibrillator or biventricular pacemaker, supine 
systolic blood pressure <85 or >200  mmHg, primary 
renal or hepatic impairment [estimated glomerular fil-
tration rate (eGFR) <30 mL/min, aspartate aminotrans-
ferase/alanine aminotransferase >2 times the upper 
limit of normal], hypokalemia (<3.5 mmol/L) or hyper-
kalemia (>5.5 mmol/L), significant anemia (hemoglobin 
<100  g/L), pregnancy, or current/previous treatment 
with a GLP-1 receptor agonist or dipeptidyl peptidase-4 
inhibitor.
The protocol was approved by the Swedish Central 
Ethical Review Board and the Medical Products Agency 
and conducted according to the principles of the Decla-
ration of Helsinki, 1975. Written informed consent was 
obtained from all participants. The trial was registered at 
http://www.isrctn.org/ISRCTN47533126.
Protocol
The trial used a randomized, crossover, double-blind 
design [22]. In summary the study protocol was per-
formed in two sessions over 2 consecutive days. After an 
overnight fast, all participants underwent intravenous 
infusion with glucose (50 mg/mL; 50 mL/h) and insulin 
[Actrapid, Novo Nordisk, Bagsværd, Denmark, 1–6 U/h 
to maintain normoglycemia (4–6  mmol/L)], and exena-
tide (0.12 pmol/kg/min) or placebo, provided by Eli Lilly 
Amylin Alliance (Indianapolis, IN, USA) in a syringe 
pump device (Ivac Medical Systems, Basingstoke, UK) for 
6  h. This was followed by an 18-h washout period. The 
placebo was the solvent used in the exenatide infusion. 
In the two-session block-randomization procedure, ten 
patients received exenatide on day 1 (Group A) followed 
by placebo on day 2. The remaining 10 patients received 
placebo on day 1 (Group B) followed by exenatide on day 
2. Hemodynamic measurements were recorded at base-
line, 1, and 6 h after the start of infusion. Blood samples 
for determining plasma ANP, NT-proBNP and exenatide 
levels were collected before the start of infusion (base-
line) and after 6 h of infusion.
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Assessment of cardiac hemodynamics
Hemodynamic measures were determined by right-heart 
catheterization (method described elsewhere [22]). Ther-
modilution catheters were inserted via the internal jugu-
lar veins. The tip of the catheter was advanced into the 
pulmonary artery to reach a position adequate for moni-
toring wedge pressure. Then, 7.5-F pulmonary artery 
thermodilution catheters (AH-05050, Arrow Interna-
tional, Inc., Bernville, PA, USA), and the Siemens Sirecust 
SC 9000XL monitor (Siemens, Denver, CO, USA) were 
used to calculate cardiac filling pressure and CO.
Invasive arterial blood pressure and heart rate 
measurements
A catheter with an arterial line primed with NaCl (0.9 %) 
was positioned in the radial artery in the right wrist of 
all patients. Calculation of HR was based on the aver-
age R–R interval over the final 10 s (Siemens Sirecust SC 
9000XL).
Biochemical analyses
ANP was determined by radioimmunoassay specific for 
h-ANP (EURIA-ANP, Euro Diagnostica, Malmö, Swe-
den). Exenatide was measured by sandwich immunoassay 
(Tandem Labs, San Diego, CA, USA). Two monoclonal 
antibodies (capture antibody and detection antibody, 
Tandem Labs, San Diego, CA, USA) were used to immo-
bilize and detect exenatide.
NT-proBNP was determined by a sandwich immunoas-
say (Roche Diagnostics Scandinavia AB). Two monoclo-
nal antibodies in a two-step procedure (capture antibody 
and detection antibody) were used to immobilize and 
detect brain natriuretic peptide (BNP). NEFA levels were 
determined using a NEFA-HR kit (Wako Chemicals, 
Neuss, Germany) on a Thermo T20xti instrument (Kone, 
Espoo, Finland).
Statistical analyses
Data are presented as mean (±standard error of the 
mean) or percentages. Normal distribution of the vari-
ables was tested with the Shapiro–Wilk test. Differences 
in paired data were evaluated using the Wilcoxon signed-
rank test. Correlations between hemodynamic variables 
and ANP were tested by Spearman’s correlation coeffi-
cients. To detect potential carry-over effects, Wilcoxon 
signed-rank tests between baseline levels for days 1 and 
2 (for each variable studied) in Group A (the group that 
received active treatment on day 1) were performed. A 
general linear mixed model with participant and time as 
repeated factors and treatment as a fixed factor was used 
to test the effect of treatment on continuous parameters 
with data for more than two time points. To test whether 
the associations between ANP and NT-proBNP, and the 
hemodynamic variables were confounded by exenatide 
concentrations, we created multivariable linear regres-
sion models with ANP and NT-proBNP, respectively, as 
the dependent variable, and exenatide concentrations 
as a covariate. The assumptions for the linear regression 
models were tested as the standardized residuals were 
plotted against standardized predicted values to test sta-
tistical independence and variance of the errors. All tests 
were two-tailed, and a P value <0.05 indicated statistical 
significance. Statistical analyses were performed using 




Baseline characteristics of the study population are 
shown in Table  1. Twenty male patients with base-
line hemodynamic variables consistent with CHF with 
a depression of CO and an elevation of PCWP were 
included in the study.
Concomitant medications
Table  1 shows all medications used by study partici-
pants. All patients were on stable doses of ACE or A-II 
inhibitors, β-blockers (except one patient), and diuret-
ics. All patients but three received antidiabetic therapy 
(12 received insulin, five received metformin and one 
received a sulfonylurea).
Carry‑over effects
We found no significant carry-over effects in any of the 
primary endpoint variables.
Hemodynamic and metabolic parameters
The results of the original study including all hemody-
namic data have been published elsewhere [22]. Hemo-
dynamic effects are shown in Table  2. Briefly, after 
6  h exenatide infusion there was a statistically signifi-
cant increase in CI (0.3 ± 0.07 L/min/m2) as a result of 
increased heart rate (8 ±  3  bpm), but with a concomi-
tant decrease in PCWP (−2.2  ±  0.9  mmHg) and RAP 
(−0.85 ± 0.7 mmHg) [22]. Stroke volume and measure-
ments of peripheral vascular tonus such as: systolic-, 
diastolic-, and mean arterial blood pressure, and systemic 
vascular resistance did not change significantly during 
the exenatide infusion, data shown elsewhere [22].
Plasma levels of ANP, NT‑proBNP and non‑esterified free 
fatty acids (NEFA), and the correlation with exenatide 
plasma levels
As expected, plasma exenatide levels increased during 
the 6 h of exenatide infusion (0.6 ± 0.5 to 132 ± 11 pmol/
mL) compared with the placebo infusion (0.6  ±  0.5 
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to 1.0  ±  0.5  pmol/L), p  <  0.001. Exenatide infu-
sion significantly decreased circulating ANP levels by 
21.9 ± 9.2 pmol/mL (Table 2) compared with an increase 
during placebo infusion of 12.5 ± 10 pmol/mL (p = 0.02). 
Exenatide did not change NT-proBNP levels (p  =  0.4; 
Table 2). Plasma levels of exenatide did not correlate with 
ANP levels (r  =  0.18, p  =  0.46), or NT-proBNP levels 
(r = 0.10, p = 0.68,) (Figs. 1, 2).
Correlations between ANP, NT‑proBNP and hemodynamic 
parameters during exenatide versus placebo infusion
There were significant positive correlations between ANP 
and RAP (r = 0.50, p = 0.029), PAP (r = 0.53, p = 0.021), 
and PCWP (r = 0.55, p = 0.015) during exenatide infu-
sion, with no such correlations during placebo infusion 
(Figs. 1, 2). All correlations remained significant in linear 
regression models after adjustment for plasma exenatide 
levels (Table  3). There were significant positive correla-
tions between NT-proBNP levels, PAP and PCWP dur-
ing both exenatide and placebo infusions, with no such 
correlation for RAP (Figs.  1, 2). During exenatide infu-
sion, ANP levels showed no correlation with NT-proBNP 
levels or CO (Figs. 1, 2).
Discussion
In the present study we found that 6-h exenatide infusion 
resulted in a significant decrease in ANP levels compared 
with placebo. No such effect was demonstrated for NT-
proBNP levels. There was no correlation between ANP 
level and exenatide level. During exenatide infusion there 
was a significant positive correlation between ANP levels 
and the following hemodynamic variables: RAP, PAP and 
PCWP, which remained significant after adjustment for 
plasma exenatide concentration. This suggests that ANP 
levels were not directly associated with exenatide levels, 
but were related to the action of the decreased filling 
pressure during exenatide infusion.
In our previous study, we demonstrated that exenatide 
infusion increased cardiac index as a result of chronot-
ropy, without any changes in stroke volume. However, 
favorable effects on cardiac filling pressures were also 
demonstrated, whereby RAP and PCWP significantly 
decreased [22]. As GLP-1 exerts pleiotropic actions on 
the cardiovascular system there may be several plausible 
explanations for our findings. GLP-1 and its analogues 
ameliorate cardiac dysfunction in several animal mod-
els of induced heart failure [23]. Some of these stud-
ies have suggested an increase in glucose use instead of 
lipid oxidation, and therefore more efficient utilization 
of the substrate [24], an issue that was beyond the scoop 
in the present study. However, as expected plasma glu-
cose remained unchanged during exenatide infusion, as 
the study subjects received insulin-glucose infusion to 
Table 1 Participant characteristics
Values are mean ± standard error of the mean or proportions
A-II receptor antagonists angiotensin-II receptor antagonists, ACEi angiotensin-
converting enzyme inhibitor, ASA aspirin, AF atrial fibrillation, BMI body 
mass index, CAD coronary artery disease, DCM dilated cardiomyopathy, eGFR 
estimated glomerular filtration rate, HbA1c glycosylated hemoglobin, HDL 
high-density lipoprotein, LDL low-density lipoprotein, LV left ventricular, CAD 




Age (years) 66 ± 1
BMI (kg/m2) 31 ± 1
Diabetes duration (years) 13 ± 2
Microalbuminuria (20–200 µg/min) 7/20
 Mean (µg/min) 36 ± 18
Macroalbuminuria (>200 µg/min) 5/20
 Mean (µg/min) 368 ± 63
Diabetic retinopathy 16/20
 None 4
 Mild non-proliferative 7
 Moderate non-proliferative 7
 Severe non-proliferative 2
HbA1c (mmol/mol) 65 ± 4
Cholesterol (mmol/l) 4.1 ± 0.3
HDL-cholesterol (mmol/l) 1.0 ± 0.1
LDL-cholesterol (mmol/l) 2.4 ± 0.2
Triacylglycerol (mmol/l) 1.4 ± 0.1
eGFR (mL/min/1.73 m2) 64 ± 7
NYHA functional class (%)
 III 55
 IV 45
LV ejection fraction (%) 26 ± 2





 Former smoker 60
 Current smoker 40
AF (%) 55
Concomitant medication (%)
 ACEi/A-II receptor antagonists 100
 Beta-blocker 95








 Combination therapy 5
 Diet only 15
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achieve normoglycemia during the study protocol. Addi-
tionally, both vasodilatation and changes in renal hemo-
dynamics could have decreased cardiac filling pressure: 
factors we were not able to control for. Even though it is 
established that GLP-1 exerts pleiotropic actions in the 
cardiovascular system it might, in the present study, be 
difficult to extrapolate blood pressure effects to those on 
vascular smooth muscle and vice versa due to heart rate 
as one confounding factor. Circulating ANP has been 
suggested as an important mediator to explain some of 
the beneficial cardiovascular actions of GLP-1 and its 
analogs [12].
It is well-known that plasma ANP is elevated in subjects 
with heart failure [25]. Atrial pressure is one major deter-
minant for the release of ANP, because circulating plasma 
ANP levels are rapidly decreased when atrial pressure is 
reduced [26]. The ability to respond quickly to changes 
in cardiac filling pressures is maintained in patients with 
severe CHF [26]. Some parallel to this can be drawn from 
the present study. Our patients were to some extent ade-
quately pharmacologically treated, as their cardiac filling 
pressure was only moderately raised, i.e., prior to rand-
omization all patients had acutely received intravenous 
diuretics because of cardiac decompensation. There was 
a rapid decrease in ANP levels during exenatide infu-
sion, which, together with reduced cardiac filling pres-
sure, may suggest a correlation between plasma exenatide 
levels. However, no such correlation was demonstrated, 
but a significant correlation between ANP levels and car-
diac filling pressure was observed. This finding merely 
reflects the reduction of atrial stretch [27, 28], rather than 
changes in ANP levels.
Both ANP and BNP levels are increased in patients 
with CHF. However BNP is a superior predictor of the 
severity of CHF [16–18, 29–31]. In the current study, 
NT-proBNP levels were strongly increased, indicating 
severe CHF. There were no changes in NT-proBNP levels 
during exenatide infusion. In contrast, there was a posi-
tive correlation between PCWP and NT-proBNP levels, 
regardless of whether exenatide or placebo was infused. 
BNP is synthesized primarily from the ventricles of the 
heart, and to a smaller degree by the atrium. Addition-
ally, different patterns in secretions of ANP and BNP 
after volume loading/or pressor enhancements have 
been demonstrated [26, 32]. In such conditions, while 
circulating ANP levels increase rapidly, changes in BNP 
levels are negligible, supporting the fact that the atrium 
contains small amounts of BNP [26, 32]. In present study 
there was a rapid decrease in PCWP concomitant with a 
rapid decrease in ANP levels during exenatide infusion, 
with no such changes in BNP levels, which is supported 
by other studies [26, 32]. This may, in part, explain why 
the correlation between BNP levels and PCWP did not 
change between exenatide and placebo infusion.
Table 2 Hemodynamic and metabolic parameters during the study
Values are mean ± standard error of the mean
CI cardiac index, RAP right atrial pressure, PAP mean pulmonary arterial pressure, PCWP pulmonary capillary wedge pressure, ANP atrial natriuretic peptide, ΔANP 
changes in ANP levels following 6 h of infusion, NT-pro-BNP N-terminal pro-brain natriuretic peptide, ΔNT-proBNP changes in ΔNT-proBNP levels following 6 h of 
infusion, NEFA non-esterified fatty acids
* p < 0.05, ** p < 0.01, *** p < 0.001 for exenatide vs placebo
a Hemodynamic and metabolic parameters prior to the protocol (before any infusions)
pb; overall p value for exenatide treatment vs. placebo over all time points (1, 3, 6 h) for every parameter, included in the model (general linear mixed model)
pc; p value for exenatide treatment vs. Placebo after 6-h infusion (Wilcoxon signed-rank tests)
Time point Baselinea 0 h 6 h P
Exenatide Placebo Exenatide Placebo
Hemodynamic
 CI (L/min) 1.8 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 2.1 ± 0.1* 1.9 ± 0.1 0.003b
 RAP (mmHg) 9.0 ± 1 7.5 ± 1 8.5 ± 1 6.6 ± 1 7.9 ± 1 0.03b
 PAP (mmHg) 28 ± 2 26 ± 2 28 ± 2 26 ± 3 29 ± 2 0.08 b
 PCWP (mmHg) 17 ± 2 14.8 ± 2 16.0 ± 2 12.6 ± 2*** 17.4 ± 2 0.001b
Metabolic
 Exenatide (pmol/l) 0.6 ± 0.5 3.5 ± 3 1.9 ± 1 132 ± 11*** 1.0 ± 0.5 0.001b
 Glucose (mmol/l) 6.6 ± 0.3 6.8 ± 0.3 7.0 ± 0.3 6.0 ± 0.3 6.0 ± 0.2 0.2b
 ANP (ρg/mL) 91.1 ± 13.3 97.1 ± 12.2 83.7 ± 13.8 78.5 ± 11.1 95.3 ± 12.7* 0.04c
 ΔANP (ρg/mL) – – – −21.9 ± 9.2 12.5 ± 10.0* 0.02c
 NT-proBNP (ng/L) 3793 ± 831 3954 ± 833 3919 ± 991 4262 ± 859 4519 ± 1182 0.4c
 ΔNT-proBNP (ng/L) – – – 307 ± 127 600 ± 249 0.5c
 NEFA (mmol/L) 0.3 ± 0.06 0.3 ± 0.1 0.3 ± 0.1 0.6 ± 0.1* 0.5 ± 0.05 0.03c
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There was no correlation between plasma exenatide 
levels and ANP levels during exenatide infusion, consist-
ent with other recent studies in humans. These studies 
have shown that GLP-1 does not mediate ANP release 
[10, 20, 21]. However, this is in contrast to a recent 
murine study from Drucker and colleagues. In their 
study, the authors clearly demonstrated that the GLP-1 
analog liraglutide mediated the release of circulating 
ANP, and led to a significant reduction of blood pressure 
because of vasorelaxation and natriuresis [12]. Because 
this finding could not be repeated in humans [20, 21, 25], 
the GLP-1–ANP axis might be species-specific. How-
ever, one recent study investigated type 2 diabetic obese 
patients, and demonstrated significant correlations in 
plasma ANP and BNP levels, and changes in liraglutide-
induced weight loss [19]. As ANP and BNP can resist 
body-fat accumulation via increasing adipocyte lipoly-
sis, the authors hypothesized that liraglutide-induced 
weight loss might be mediated by changes in circulating 
ANP and BNP levels [19], and not directly by GLP-1R. 
Although it has to be emphasized that the present study 
involved type 2 diabetes subjects with decompensated 
heart failure, and consequently these results cannot be 
generalized into a population without heart failure.
One marker of lipolysis is NEFA. In the current 
study, NEFA plasma levels were increased, both dur-
ing exenatide and placebo infusion, compared with 
baseline. During exenatide infusion, NEFA levels were 
Fig. 1 Correlations between ANP, NT-proBNP, exenatide concentrations and hemodynamic parameters after 6 h of exenatide infusion
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Fig. 2 Correlations between ANP, NT-proBNP, exenatide concentrations and hemodynamic parameters after 6 h of exenatide infusion
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further increased without any changes in other meta-
bolic parameters, i.e., glucose, insulin, C-peptide, 
glucagon and lactate levels. Importantly there was no 
correlation between plasma exenatide levels and ANP 
levels. With a lack of changes in metabolic parameters 
and no correlation observed between exenatide and 
ANP levels, it is more likely that factors such as tachy-
cardia, i.e., reflecting a hyperadrenergic state, underlies 
the increased NEFA levels observed during exenatide 
infusion. Interestingly, ANP-induced lipolysis was 
shown to be species-specific, an effect that only occurs 
in primate fat cells [33]. This finding considers that other 
ANP effects, such as the GLP-R–ANP axis, also might be 
species-specific [12].
One strength of our study is the double-blinded, pla-
cebo-controlled, cross-over design. In addition, the inva-
sive pulmonary artery catheter method remains the gold 
standard for monitoring cardiac filling pressure.
Several limitations of the study also must be noted. 
This study was not originally designed to investigate the 
effects of exenatide on neuropeptides, and the analyses of 
ANP and BNP were performed post hoc. ANP (and BNP) 
have natriuretic effects. In the current study, the decrease 
in filling pressure, evoked by exenatide, might simply be 
the result of increased natriuresis [10, 21], or even the 
indirect effect of the release of ANP [12]. We did not con-
trol for natriuresis. However, others have clearly demon-
strated that the natriuretic effects evoked by GLP-1 [21] 
or liraglutide [10] are not mediated via ANP secretion. 
Finally, as this study was a cross-sectional, we cannot 
draw any conclusions regarding the pathophysiological 
significance of our findings.
Conclusions
Our study demonstrates that short-term exenatide infu-
sion resulted in a significant decrease in circulating ANP 
levels. There was no correlation between ANP level and 
exenatide level. During exenatide infusion there was a 
significant positive correlation between ANP levels and 
cardiac filling pressure, independent of exenatide levels.
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